Stanton B. Elias

Dana-Farber Cancer Institute

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Michael Chopp

Henry Ford Health System

Stanley H. Appel

Houston Methodist

Mirela Cerghet

Henry Ford Health System

Mei Lü

Jinshan Hospital of Fudan University

Lonni Schultz

Henry Ford Health System

Yi Li

University of California System

Jieli Chen

Peking University Shenzhen Hospital

Howard Feit

Henry Ford Hospital

Steven R. Levine

SUNY Downstate Health Sciences University

Jade Borneman

Fisher Bioservices (United States)

Cooperative Institutions

NeuroRx Research (Canada)

202

Vrije Universiteit Amsterdam

197

Henry Ford Hospital

Henry Ford Health System

Inserm

Cleveland Clinic

Charité - Universitätsmedizin Berlin

University College London

Heinrich Heine University Düsseldorf

Neurology, Inc

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Cerebral venous thrombosis due to protein S deficiency in pregnancy

The Lancet (2002)

Jorge G. Burneo Stanton B. Elias Gregory L. Barkley

Protein S deficiency

Intracranial Thrombosis

10.1016/s0140-6736(02)07934-5

Cite

Citations (10)

Oligodendrocyte Development and the Natural History of Multiple Sclerosis

Archives of Neurology (1987)

Stanton B. Elias

• The cause of multiple sclerosis (MS) is not known. This article presents a review of recent studies concerned with the development of oligodendrocytes and suggests that the primary lesion in MS could be related to damage to oligodendroglial progenitor cells. Loss of the capacity to generate oligodendrocytes could alter the course of normal development such that insufficient cells are produced to support growth and replace cells lost through attrition, and as a result, regions of demyelination appear. The site and extent of the primary loss of oligodendroglial precursors would then predetermine the time of onset, site, and severity of the neurologic manifestations of MS. It is suggested that MS is a single, continuous process and that clinical, pathologic, and immunologic findings may be understood as the consequences of the acquired inability to generate sufficient oligodendrocytes to maintain myelin.

10.1001/archneur.1987.00520240066016

Cite

Citations (17)

Bone Marrow Stromal Cells Increase Oligodendrogenesis after Stroke

Journal of Cerebral Blood Flow & Metabolism (2009)

Jing Zhang Yi Li Zheng Gang Zhang Mei Lü Jade Borneman

Oligodendrocytes are sensitive to ischemic damage. The Sonic hedgehog (Shh) pathway is critical in oligodendrogenesis; Gli1 is the principal effector of Shh signaling. We investigated oligodendrogenesis and Shh/Gli1 pathway activation after bone marrow stromal cell (BMSC) treatment of stroke in rats. Rats were subjected to the middle cerebral artery occlusion (MCAo). BMSCs have been shown to promote functional recovery post stroke. A therapeutic dose of BMSC (3 x 10(6) cells) treatment was initiated 1 day after MCAo. Immunohistochemistry was carried out to measure the oligodendrocyte progenitor cells, oligodendrocytes, myelin, and expressions of Shh and Gli1 at 14 days after MCAo. Gene expression of Shh and Gli1 was tested at 2 days after MCAo. An in vitro study was used to investigate the effects of BMSC on a premature oligodendrocyte cell line (N20.1 cells). BMSC treatment significantly increased O4(+) oligodendrocytes, MBP(+) area, and bromodeoxyuridine (BrdU)(+), NG2(+), BrdU(+)-NG2(+) cells, and mRNA and protein expressions of Shh and Gli1 in the ipsilateral brain of the MCAo rats than that in phosphate buffered saline (PBS)-treated rats. BMSCs promoted N20.1 cell proliferation and Gli1 mRNA expression, and these effects were abolished by the Shh pathway inhibitor cyclopamine. These data indicate that the BMSC treatment stimulates oligodendrogenesis by activation of the Shh/Gli1 pathway post stroke.

Cyclopamine

GLI1

10.1038/jcbfm.2009.41

Cite

Citations (50)

Current Concepts of Pathogenesis and Treatment of Myasthenia Gravis

Medical Clinics of North America (1979)

Stanton B. Elias Stanley H. Appel

Pathogenesis

10.1016/s0025-7125(16)31672-8

Cite

Citations (20)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Neurology (2016)

Gavin Giovannoni Jeffrey Cohen Alasdair Coles Hans-Peter Hartung Eva Havrdová

Objective:

To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy.

Methods:

Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compared efficacy and safety of alemtuzumab 12 mg with subcutaneous interferon-β-1a (SC IFN-β-1a) 44 μg in patients with RRMS. Prespecified and post hoc disability outcomes based on Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), and Sloan low-contrast letter acuity (SLCLA) are reported, focusing on improvement of preexisting disability in addition to slowing of disability accumulation.

Results:

Alemtuzumab-treated patients were more likely than SC IFN-β-1a–treated patients to show improvement in EDSS scores (p < 0.0001) on all 7 functional systems. Significantly more alemtuzumab patients demonstrated 6-month confirmed disability improvement. The likelihood of improved vs stable/worsening MSFC scores was greater with alemtuzumab than SC IFN-β-1a (p = 0.0300); improvement in MSFC scores with alemtuzumab was primarily driven by the upper limb coordination and dexterity domain. Alemtuzumab-treated patients had more favorable changes from baseline in SLCLA (2.5% contrast) scores (p = 0.0014) and MSFC + SLCLA composite scores (p = 0.0097) than SC IFN-β-1a–treated patients.

Conclusions:

In patients with RRMS and inadequate response to prior disease-modifying therapies, alemtuzumab provides greater benefits than SC IFN-β-1a across several disability outcomes, reflecting improvement of preexisting disabilities.

Classification of evidence:

This study provides Class I evidence (based on rater blinding and a balance in baseline characteristics between arms) that alemtuzumab modifies disability measures favorably compared with SC IFN-β-1a.

10.1212/wnl.0000000000003319

Cite

Citations (57)

Abstract PS2-23: The Associations of Medication Adherence with Employment and Work Disability Among Patients with Relapsing Remitting Multiple Sclerosis

Clinical Medicine & Research (2008)

Kaan Tunceli Mirela Cerghet Elizabeth Dobie Stanton B. Elias Manel Pladevall

Kaan Tunceli, PhD, Mirela Cerghet, MD, Elizabeth A. Dobie, MPH, Stanton Elias, MD, Manel Pladevall, PhD, Lonni Schultz, PhD and Jennifer E. Lafata, PhD Kaan Tunceli, PhD, Center for Health Services Research, Henry Ford Hospital; Mirela Cerghet, MD, Henry Ford Hospital; Elizabeth A. Dobie, MPH, Henry Ford Hospital; Stanton Elias, MD, Henry Ford Hospital; Manel Pladevall, PhD, Henry Ford Hospital; Lonni Schultz, PhD, Henry Ford Hospital; Jennifer E. Lafata, PhD, Henry Ford Hospital

10.3121/cmr.6.3-4.148-a

Cite

Citations (0)

Disease course and treatment of neurosarcoidosis in a single center cohort study of 113 cases

Muhammad Affan Mohammed Kananeh Lonni Schultz Stanton B. Elias Mirela Cerghet

Neurosarcoidosis

Center (category theory)

Single Center

Source

Cite

Citations (1)

The cholinergic synapse (progress in brain research, vol 49) Edited by Stanislav Tucek Elsevier/North‐Holland Biomedical Press, Amsterdam, 1979 511 pp, illustrated, $92.75

Annals of Neurology (1981)

Stanton B. Elias

Annals

10.1002/ana.410100222

Cite

Citations (0)

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

The Lancet (2018)

Ludwig Kappos Amit Bar‐Or Bruce Cree Robert J. Fox Gavin Giovannoni

Clinical endpoint

10.1016/s0140-6736(18)30475-6

Cite

Citations (799)

Longitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosis

International Journal of MS Care (2014)

Mio Nakamura Mark Morris Mirela Cerghet Lonni Schultz Stanton B. Elias

Magnetic resonance imaging (MRI) is widely used in clinical practice, and "abnormal brain MRI" findings often prompt assessment for multiple sclerosis (MS), even when there are no symptoms suggestive of the disease. Despite several studies involving individuals with "radiologically isolated syndrome" (RIS), little is known about what factors might predict future development of MS. The objective of this study was to longitudinally evaluate clinical and MRI characteristics of people who presented to an MS clinic because of incidental abnormal MRI findings but did not have typical symptoms of MS, in order to assess risk factors for developing MS.Thirty consecutive patients presenting to an MS clinic for evaluation of abnormal MRI findings were enrolled in the study. Clinical and paraclinical data, including MRI results, were reviewed. Magnetic resonance imaging findings of T2 hyperintensities measuring more than 3 mm in diameter and fulfilling at least three out of four Barkhof criteria, with or without gadolinium-enhancing lesions, were considered to be suggestive of MS.The median follow-up time was 5.5 years. No participants without MRI findings suggestive of MS were diagnosed with MS (P = .005). Fifteen participants had MRI findings suggestive of MS. Seven of the 15 (47%) were diagnosed with MS on follow-up. Cerebrospinal fluid (CSF) testing results were available for 15 participants. Abnormal results were found in six participants, of whom five (83%) also had MRI findings suggestive of MS. Only two of the nine (22%) participants with normal CSF results (P = .04) had MRI findings suggestive of MS.In our cohort, none of the participants without MRI findings suggestive of MS developed MS. The participants with MRI findings suggestive of MS were more likely to develop symptoms and MRI changes typical of MS on follow-up.

Presentation (obstetrics)

10.7224/1537-2073.2013-016

Cite

Citations (10)